FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134723850> ?p ?o ?g. }

• W3134723850 endingPage "161" @default.
• W3134723850 startingPage "161" @default.
• W3134723850 abstract "161 Background: In the prospective CARD trial (NCT02485691), cabazitaxel significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer who had received docetaxel and progressed within 12 months with the alternative androgen-signaling-targeted inhibitor. Here we analyzed circulating tumor cell (CTC) counts as a biomarker of prognosis and response to therapy. Methods: Blood samples collected at screening (SC), Cycle 2 (C2) Day 1, and end of therapy were sent to Epic Sciences for CTC analysis. The association between CTC counts, defined as any cytokeratin-positive, CD45-negative cell, and clinical outcomes were pre-specified and analyzed using a multivariate Cox model for time-to-events (rPFS, OS) or a Χ 2 test for categorical outcomes (objective tumor response). Results: Of the 255 patients randomized, 237 (92.9%) had evaluable samples at SC and 213 (83.5%) at C2. CTCs ≥ 1 were detected in 204 samples at SC (86%) and 178 samples at C2 (84%), with a median (interquartile range) count per mL of blood of 4.1 (1.3–14.2) and 5.2 (1.5–17.3), respectively. At baseline, higher CTC counts were associated with higher values of lactate dehydrogenase (P = 0.014), alkaline phosphatase (P < 0.001), and prostate-specific antigen (P < 0.001). High CTC counts, measured as a continuous variable at SC (all arms combined) were associated with a shorter OS (P = 0.03), but not rPFS (P = 0.7). However, favorable changes in absolute CTC count from SC to C2, all arms combined, were associated with longer rPFS (P = 0.03). Conversion from high (≥ 3) to low (< 3) CTC count at C2 or maintenance of a low CTC count at C2 was associated with objective tumor response (P = 0.007). Analysis of the associations of CTC androgen receptor variant 7, chromosomal instability, heterogeneity status (Shannon Index), single-cell genotypes (e.g. retinoblastoma/phosphatase and tensin homolog copy-loss), and the presence of CTCs with small-cell/neuroendocrine morphology is ongoing. Conclusions: This preplanned analysis of the CARD trial confirms that baseline CTC counts, measured by Epic Sciences platform, are prognostic. Moreover, early favorable changes in CTC counts from baseline to C2 are associated with response to therapy. Funding: Sanofi. Clinical trial information: NCT02485691." @default.
• W3134723850 created "2021-03-15" @default.
• W3134723850 creator A5004985848 @default.
• W3134723850 creator A5007779528 @default.
• W3134723850 creator A5020692060 @default.
• W3134723850 creator A5020954030 @default.
• W3134723850 creator A5021507976 @default.
• W3134723850 creator A5024147987 @default.
• W3134723850 creator A5030195416 @default.
• W3134723850 creator A5038825854 @default.
• W3134723850 creator A5041610986 @default.
• W3134723850 creator A5048105827 @default.
• W3134723850 creator A5057407696 @default.
• W3134723850 creator A5061253538 @default.
• W3134723850 creator A5071855452 @default.
• W3134723850 creator A5078910130 @default.
• W3134723850 creator A5080347550 @default.
• W3134723850 creator A5086848806 @default.
• W3134723850 date "2021-02-20" @default.
• W3134723850 modified "2023-09-25" @default.
• W3134723850 title "CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial." @default.
• W3134723850 doi "https://doi.org/10.1200/jco.2021.39.6_suppl.161" @default.
• W3134723850 hasPublicationYear "2021" @default.
• W3134723850 type Work @default.
• W3134723850 sameAs 3134723850 @default.
• W3134723850 citedByCount "2" @default.
• W3134723850 countsByYear W31347238502022 @default.
• W3134723850 crossrefType "journal-article" @default.
• W3134723850 hasAuthorship W3134723850A5004985848 @default.
• W3134723850 hasAuthorship W3134723850A5007779528 @default.
• W3134723850 hasAuthorship W3134723850A5020692060 @default.
• W3134723850 hasAuthorship W3134723850A5020954030 @default.
• W3134723850 hasAuthorship W3134723850A5021507976 @default.
• W3134723850 hasAuthorship W3134723850A5024147987 @default.
• W3134723850 hasAuthorship W3134723850A5030195416 @default.
• W3134723850 hasAuthorship W3134723850A5038825854 @default.
• W3134723850 hasAuthorship W3134723850A5041610986 @default.
• W3134723850 hasAuthorship W3134723850A5048105827 @default.
• W3134723850 hasAuthorship W3134723850A5057407696 @default.
• W3134723850 hasAuthorship W3134723850A5061253538 @default.
• W3134723850 hasAuthorship W3134723850A5071855452 @default.
• W3134723850 hasAuthorship W3134723850A5078910130 @default.
• W3134723850 hasAuthorship W3134723850A5080347550 @default.
• W3134723850 hasAuthorship W3134723850A5086848806 @default.
• W3134723850 hasConcept C119060515 @default.
• W3134723850 hasConcept C121608353 @default.
• W3134723850 hasConcept C126322002 @default.
• W3134723850 hasConcept C126894567 @default.
• W3134723850 hasConcept C143998085 @default.
• W3134723850 hasConcept C185592680 @default.
• W3134723850 hasConcept C2775832370 @default.
• W3134723850 hasConcept C2776551883 @default.
• W3134723850 hasConcept C2777899217 @default.
• W3134723850 hasConcept C2778971682 @default.
• W3134723850 hasConcept C2779013556 @default.
• W3134723850 hasConcept C2780192828 @default.
• W3134723850 hasConcept C2780739268 @default.
• W3134723850 hasConcept C2781190966 @default.
• W3134723850 hasConcept C2781197716 @default.
• W3134723850 hasConcept C3019894029 @default.
• W3134723850 hasConcept C55493867 @default.
• W3134723850 hasConcept C61238886 @default.
• W3134723850 hasConcept C61367390 @default.
• W3134723850 hasConcept C71924100 @default.
• W3134723850 hasConceptScore W3134723850C119060515 @default.
• W3134723850 hasConceptScore W3134723850C121608353 @default.
• W3134723850 hasConceptScore W3134723850C126322002 @default.
• W3134723850 hasConceptScore W3134723850C126894567 @default.
• W3134723850 hasConceptScore W3134723850C143998085 @default.
• W3134723850 hasConceptScore W3134723850C185592680 @default.
• W3134723850 hasConceptScore W3134723850C2775832370 @default.
• W3134723850 hasConceptScore W3134723850C2776551883 @default.
• W3134723850 hasConceptScore W3134723850C2777899217 @default.
• W3134723850 hasConceptScore W3134723850C2778971682 @default.
• W3134723850 hasConceptScore W3134723850C2779013556 @default.
• W3134723850 hasConceptScore W3134723850C2780192828 @default.
• W3134723850 hasConceptScore W3134723850C2780739268 @default.
• W3134723850 hasConceptScore W3134723850C2781190966 @default.
• W3134723850 hasConceptScore W3134723850C2781197716 @default.
• W3134723850 hasConceptScore W3134723850C3019894029 @default.
• W3134723850 hasConceptScore W3134723850C55493867 @default.
• W3134723850 hasConceptScore W3134723850C61238886 @default.
• W3134723850 hasConceptScore W3134723850C61367390 @default.
• W3134723850 hasConceptScore W3134723850C71924100 @default.
• W3134723850 hasIssue "6_suppl" @default.
• W3134723850 hasLocation W31347238501 @default.
• W3134723850 hasOpenAccess W3134723850 @default.
• W3134723850 hasPrimaryLocation W31347238501 @default.
• W3134723850 hasRelatedWork W122177069 @default.
• W3134723850 hasRelatedWork W2135620818 @default.
• W3134723850 hasRelatedWork W2263206436 @default.
• W3134723850 hasRelatedWork W2415481598 @default.
• W3134723850 hasRelatedWork W2520434430 @default.
• W3134723850 hasRelatedWork W2568045406 @default.
• W3134723850 hasRelatedWork W2768688864 @default.
• W3134723850 hasRelatedWork W2783882412 @default.
• W3134723850 hasRelatedWork W3023947295 @default.
• W3134723850 hasRelatedWork W4229076799 @default.

• next